Sandeep Sur, general manager, Novo Nordisk Indonesia accepts the CSR Award in Jakarta

Global research company Frost & Sullivan has named Novo Nordisk as the Diabetes CSR Company of the Year. The acknowledgement recognizes the company’s long-term commitment to improving diabetes care in Indonesia.

“As a leading diabetes care company we are committed to work closely with local partners to improve diabetes education and awareness in Indonesia”, said Sandeep Sur, general manager, Novo Nordisk Indonesia. “We are very honoured about this recognition given by Frost & Sullivan and will continue our journey of changing diabetes in Indonesia.”

Indonesia has the 7^th highest number of people living with diabetes in the world with an estimated 8.5 million people.[1] Due to poor access to healthcare and limited quality of care, less than 1% of Indonesians living with diabetes are achieving internationally recommended blood sugar levels.[2]

In 2003, Novo Nordisk in a concerted action with partners, started investing in response to the rise in diabetes, strengthening healthcare professional education, establishing diabetes care centres in rural areas and increasing awareness about diabetes and its risk factors.

Frost & Sullivan commend Novo Nordisk’s decade of social responsibility, calling attention to the company’s outperformance of peers on 4 criteria - Growth strategy excellence, Growth implementation excellence, Degree of innovation with new products and technology, and Leadership in customer value and market penetration.

In the award report, Frost & Sullivan states:

Novo Nordisk has proven its leadership in CSR in the Indonesian diabetes care market through its dedicated focus on improving quality of life for diabetics through its patient-focused activities along with a significant degree of innovation through its range of solutions to support treatment.

In a 2013 business case, Where economics and health meet: changing diabetes in Indonesia, Novo Nordisk analysed the economic and societal benefits of its operations. The business case aims to identify ways the company can work together with governmental and non-governmental partners to scale up successful projects, programmes and initiatives in Indonesia benefitting patients and the diabetes care community.

Download the business case

The award was presented to Sandeep Sur, General Manager PT Novo Nordisk Indonesia in Jakarta on 23 September 2014.

About the Best Practice Awards

Frost & Sullivan’s Best Practices Awards recognise companies throughout a range of regional and global markets for superior leadership, technological innovation, customer service, and strategic product development. Frost & Sullivan's industry analyst team benchmarks market participants and measures their performance through independent, primary interviews, and secondary industry research in order to evaluate and identify best practices

Read more about the Frost & Sullivan Best Practice Awards

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk